Cholecystokinin (CCK) has been suggested to be both pro-nociceptive and ''anti-opioid'' by actions on pain-modulatory cells within the rostral ventromedial medulla (RVM). One consequence of activation of RVM CCK 2 receptors may be enhanced spinal nociceptive transmission; but how this might occur, especially in states of pathological pain, is unknown. Here, in vivo microdialysis was used to demonstrate that levels of RVM CCK increased by approximately 2-fold after ligation of L 5 /L 6 spinal nerves (SNL). Microinjection of CCK into the RVM of naïve rats elicited hypersensitivity to tactile stimulation of the hindpaw. In addition, RVM CCK elicited a time-related increase in (prostaglandin-E 2 ) PGE 2 measured in cerebrospinal fluid from the lumbar spinal cord. The peak increase in spinal PGE 2 was approximately 5-fold and was observed at approximately 80 minutes post-RVM CCK, a time coincident with maximal RVM CCK-induced mechanical hypersensitivity. Spinal administration of naproxen, a nonselective COX-inhibitor, significantly attenuated RVM CCK-induced hindpaw tactile hypersensitivity. RVM-CCK also resulted in a 2-fold increase in spinal 5-hydroxyindoleacetic acid (5-HIAA), a 5-hydoxytryptophan (5-HT) metabolite, as compared with controls, and mechanical hypersensitivity that was attenuated by spinal application of ondansetron, a 5-HT 3 antagonist. The present studies suggest that chronic nerve injury can result in activation of descending facilitatory mechanisms that may promote hyperalgesia via ultimate release of PGE 2 and 5-HT in the spinal cord. Ó
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Introduction
Chronic pain is thought to be associated with engagement of descending pain-facilitatory mechanisms from areas of the brainstem including the rostral ventromedial medulla (RVM) [4, 17, 67] . However, it is unclear how descending facilitation may alter the release of transmitters that may act to promote nociception at the level of the spinal cord under physiological or pathological pain states. A number of studies suggest that cholecystokinin (CCK) can activate the descending pain-facilitatory system from the RVM [18, 22, 23, 65] . CCK is co-localized in pain-related regions of the CNS including the RVM [19, 66] and produces its action at CCK, G as -coupled receptors. Recently, we demonstrated CCK 2 receptors are co-localized on putative RVM pain facilitatory neurons with l-opioid receptors [66] . Microinjection of CCK into the RVM produces hyperalgesia via activation of CCK 2 receptors [65] .
RVM CCK antagonists can enhance the antinociceptive effects of acute opioid administration [10, 16] . Hyperalgesia that is observed after sustained systemic administration of morphine [56, 57] is reversed by blockade of RVM CCK 2 -receptors [65] . Studies performing RVM microdialysis have demonstrated that CCK is increased 4-fold after sustained morphine administration [65] , suggesting that endogenous CCK may drive descending pain facilitation. CCK 2 antagonists within the RVM are effective in reversing hypersensitivity resulting from nerve injury or visceral hyperalgesia, thus suggesting endogenous CCK is up-regulated in the RVM in pathological pain states [18, 30] . CCK has been demonstrated to be both pro-nociceptive, by directly activating ON cells, and antiopioid, by inhibiting the activation of OFF cells [23, 46] . Although a role for endogenous RVM-CCK in states of pathological pain have been suggested through antagonist studies, it is not known whether increased expression of CCK occurs and the possible consequences at the level of the spinal cord. 
